हमारा समूह 1000 से अधिक वैज्ञानिक सोसायटी के सहयोग से हर साल संयुक्त राज्य अमेरिका, यूरोप और एशिया में 3000+ वैश्विक सम्मेलन श्रृंखला कार्यक्रम आयोजित करता है और 700+ ओपन एक्सेस जर्नल प्रकाशित करता है जिसमें 50000 से अधिक प्रतिष्ठित व्यक्तित्व, प्रतिष्ठित वैज्ञानिक संपादकीय बोर्ड के सदस्यों के रूप में शामिल होते हैं।
ओपन एक्सेस जर्नल्स को अधिक पाठक और उद्धरण मिल रहे हैं
700 जर्नल और 15,000,000 पाठक प्रत्येक जर्नल को 25,000+ पाठक मिल रहे हैं
Jun Ueda, Hiroshi Funakoshi
Epigenome editing is fast becoming a promising technology for use in not only basic research but also various medical fields. Its applications are being studied for treatment of various diseases, including cancer, genetic diseases, and infectious diseases. Viral infections are known to cause epigenetic modifications in the host. Therefore, epigenome editing is a promising therapeutic approach which also has the capability to downregulate receptors for pathogen to enter the host. However, addressing the challenges of drug delivery systems is an essential and critical component for the success of these approaches. In this review, we briefly introduce the distinctive differences between genome editing and epigenome editing, highlight the challenges in application of the epigenome-editing approach to infectious diseases, and briefly outline the recent advances and challenges in drug delivery systems that are essential for therapeutic applications of epigenome editing. While further advances in delivery systems are needed, epigenome editing could be a potentially new generation of treatments and open new avenues for treating infectious diseases, in addition to genetic and other diseases.